New adaptive radiotherapy technique for head and neck cancer can deliver a more robust treatment plan in a shorter timeframe on MR Linac, compared with the current method used by most radiotherapy centres.

Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.